Initiator Pharma A/S

Equities

INIT

DK0060775872

Biotechnology & Medical Research

Market Closed - Nasdaq Stockholm Other stock markets 12:00:00 2024-07-16 EDT			5-day change	1st Jan Change
9.05 ^SEK	+1.12%		-1.63%	-2.06%

05-10	Initiator Pharma A/S Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
02-23	Initiator Pharma A/S Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	CI

Initiator Pharma A/S has filed an IPO in the amount of SEK 20.46929 million.

January 16, 2017 at 12:00 am

Initiator Pharma A/S has filed an IPO in the amount of SEK 20.46929 million. Security Name: Shares Security Type: Common Stock Securities Offered: 3,721,689 PriceRange: SEK 5.5 Transaction Features: Rights Offering

Latest news about Initiator Pharma A/S

Initiator Pharma A/S Reports Earnings Results for the First Quarter Ended March 31, 2024	05-10	CI
Initiator Pharma A/S Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	02-22	CI
Initiator Pharma Issues New Shares for Debt Conversion	02-21	MT
Initiator Pharma A/S Expands Its Position to Broader Sexual Health Franchise and Intends Business Development Efforts	01-08	CI
Initiator Pharma A/S Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-10	CI
Initiator Pharma A/S Announces Positive Results from Phase IIb Clinical Trial with Pudafensine	23-10-06	CI
Initiator Pharma A/S Announces Indication Expansion - Clinical Drug Candidates Active in Models of Female Sexual Dysfunction	23-09-19	CI
Initiator Pharma A/S Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-25	CI
Initiator Pharma Wins EU Patent for Erectile Dysfunction, Depression Drug Candidate	23-08-09	MT
Initiator Pharma A/S Obtains IP 2018 Patent in Europe for Treatment of Erectile Dysfunction and Depression	23-08-09	CI
Initiator Pharma A/S Announces Positive Results from Pudafensine Phase I Pharmacokinetic Trial	23-07-18	CI
Initiator Pharma A/S (OM:INIT) commences an Equity Buyback Plan for 10% of its issued share capital, under the authorization approved on May 26, 2023.	23-07-05	CI
Initiator Pharma A/S Completes Recruitment in Phase IIb Trial with Pudafensine	23-06-29	CI
Initiator Pharma A/S Reports Dose-Dose-Dose-dependent Significant Erectile Dysfunction of IP 2018 in the Placebo-Controlled Phase IIa Clinical Trial of Erectile Dysfunction	23-06-05	CI
Initiator Pharma A/S's Equity Buyback announced on July 25, 2022 has expired.	23-05-25	CI
Initiator Pharma A/S Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-05	CI
Tranche Update on Initiator Pharma A/S (OM:INIT)'s Equity Buyback Plan announced on July 25, 2022.	23-05-02	CI
Initiator Pharma A/S Reports Earnings Results for the Full Year Ended December 31, 2022	23-05-02	CI
Initiator Pharma A/S Completes Dosing in Phase 2a Trial with IP2018	23-03-06	CI
Initiator Pharma A/S Ready to Start Phase I Pharmacokinetics Study for New IP2015 Formulations	22-12-20	CI
Tranche Update on Initiator Pharma A/S (OM:INIT)'s Equity Buyback Plan announced on July 25, 2022.	22-11-04	CI
Initiator Pharma A/S Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-04	CI
Initiator Pharma A/S Provides an Update on Its Clinical Programs	22-11-04	CI
Certain Ordinary Shares of Initiator Pharma A/S are subject to a Lock-Up Agreement Ending on 3-OCT-2022.	22-10-02	CI
Initiator Pharma A/S Reports the Final Analysis of Positive Efficacy Data from the IPTN2021 Program Phase I Study	22-09-21	CI

Chart Initiator Pharma A/S

Duration

Period

More charts

Company Profile

Initiator Pharma A/S is a Denmark-based company engaged in the biotechnology sector. The Company focuses on developing drugs for treatment of erectile dysfunction.

Sector

Biotechnology & Medical Research

Calendar

2024-08-22 - Q2 2024 Earnings Release

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
INITIATOR PHARMA A/S	-2.06%	44.76M
MODERNA, INC.	+25.00%	46.56B
LONZA GROUP AG	+45.38%	41.67B
IQVIA HOLDINGS INC.	+0.17%	41.16B
ALNYLAM PHARMACEUTICALS, INC.	+33.18%	32.4B
ICON PUBLIC LIMITED COMPANY	+20.92%	28.18B
CELLTRION, INC.	-6.35%	28.1B
UNITED THERAPEUTICS CORPORATION	+48.82%	14.52B
MEDPACE HOLDINGS, INC.	+47.12%	13.74B
BIO-TECHNE CORPORATION	+3.28%	12.17B

Other Biotechnology & Medical Research

Initiator Pharma A/S

Equities

INIT

DK0060775872

Biotechnology & Medical Research

Initiator Pharma A/S has filed an IPO in the amount of SEK 20.46929 million.

Latest news about Initiator Pharma A/S

Chart Initiator Pharma A/S

Company Profile

Income Statement Evolution

EPS Revisions

Annual profits - Rate of surprise

Sector Other Biotechnology & Medical Research